Browse > Article
http://dx.doi.org/10.3746/jkfn.2004.33.8.1294

The Effects of Isoflavone Supplementation on Serum PSA, Lipid Profile, Antioxidant and Immune System in Prostate Cancer Patients  

Lee, Joo-Min (Dept. of Food and Nutrition, Yonsei University)
Hong, Sung-Joon (Dept. of Urology, College of Medicine, Yonsei University)
Lee, Min-June (Research Institute of Food and Nutritional Sciences, Yonsei University)
Yoon, Sun (Dept. of Food and Nutrition, Yonsei University)
Publication Information
Journal of the Korean Society of Food Science and Nutrition / v.33, no.8, 2004 , pp. 1294-1301 More about this Journal
Abstract
Soy foods are a unique dietary source of isoflavones, which have effects relevant to prostate cancer prevention. The present study determines the effects of a short-term isoflavone supplement on serum PSA (prostate specific antigen), lipid profile, antioxidant status, and immune system in prostate cancer patients. Ten prostate cancer patients were supplemented daily with 150 mg of isoflavone for 2 months. Blood samples were collected baseline and 2 month after for analysis of PSA, serum lipid profiles, total antioxidant status (TAS), grade of DNA damage in lymphocytes, IL-6, VEGF and TNF -$\alpha$. After 2 month isoflavone supplementation, increased significantly a total of estimated urinary isoflavone excretion and did not change PSA. Serum lipid profiles showed significant change in serum total cholesterol level (p=0.007). However, there was no significant change in HDL- and LDL-cholesterol levels. TAS was increased but not significant after isoflavone supplementation. Tail moment (TM) was decreased and especially tail length (TL) was decreased significantly (p=0.043). IL-6 level was decreased but VEGF level and TNF -$\alpha$ level were increased. The results of the present study led to the conclusion that the isoflavone dosage (150 mg) in supplement had positive effects on the serum total cholesterol level and DNA damage.
Keywords
isoflavone; prostate cancer; prostate specific antigen (PSA); antioxidant status; lipid profiles;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kapiotis S, Hermann M, Held I, Seelos C, Ehringer H, Gmeiner BM. 1997. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 17: 2868-2674   DOI   ScienceOn
2 Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. 1997. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 26: 63-70   DOI   ScienceOn
3 Sargeant P, Farndale RW, Sage SO. 1993. The tyrosine kinase inhibitors methyl 2,5-dihydroxycinnimate and genistein reduce thrombin-evoked tyrosine phophorylation and $Ca^2^+$ entry in human platelets. FEBS Letters 315: 242 -246   DOI   ScienceOn
4 King RA, Bursill DB. 1998. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67: 867-872   DOI
5 Jarred RA, Keikha M, Dowling C. 2002. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 11: 1689-1696
6 Wilcox JN, Blumenthal BF. 1995. Thrombotic mechanisms in atherosclerosis: potential impact of soy protein. J Nutr 125: 631S-638S
7 Akiyama T, Ishida J, Nakagava S, Ogawara S, Watanabe S, Itoh N, Shiyba M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595
8 Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. 2001. Interleukin-6 and prostate cancer progression. Cytokine & Growth Factor Reviews 12: 33-40   DOI   ScienceOn
9 Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. 1999. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187   DOI   ScienceOn
10 Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. 1999. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133   DOI   ScienceOn
11 Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris AL. 2000. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85: 276-280   DOI   ScienceOn
12 Lucia MS, Torkko KC. 2004. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171: S30-S35   DOI   ScienceOn
13 Duque JLF, Loughlin KR, Adam RM. 1999. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523- 527   DOI   ScienceOn
14 Turner K, Jones A. 2000. Vascular endothelial growth factor in prostate cancer. Urology 56: 183
15 Kollermann J, Helpap B. 2001. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116: 115-121   DOI   ScienceOn
16 Davis JN, Kucuk O, Djuric Z, Sarkar FH. 2001. Soy isoflavone supplementation in healthy men prevents NF- kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30: 1293-1302   DOI   ScienceOn
17 Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. 1999. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18: 3166-3172   DOI   ScienceOn
18 Morris SM, Chen JJ, Domon OE, McGarrity LJ, Bishop ME, Manjanatha MG, Casciano DA. 1998. P53, mutation and apoptosis in genistein-exposed human lymphoblastoid cells. Mutat Res 405: 41-56   DOI   ScienceOn
19 Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie AW, Constantinou AI. 2000. Genistein induces apoptosis and topoisomerase Π-mediated DNA breakage in colon cancer cells. Eup J Cancer 36: 796-802   DOI   ScienceOn
20 Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. 1992. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200- 6208
21 Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Jeffcoat RA, Crowell J, Paglieri J, Zeisel SH. 2003. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77: 875-882   DOI
22 Mitchell JH, Collins AR. 1999. Effects of a soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men-a pilot study. Eur J Nutr 38: 143-148   DOI   ScienceOn
23 Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O. 2001. Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Letters 172: 1-6   DOI   ScienceOn
24 Messina MJ, Persky V, Setchell KD, Barnes S. 1994. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113-131   DOI   ScienceOn
25 Affenito SG, Kerstetter J. 1999. Position of the American dietetic association and dietitians of Canada: women's health and nutrition. J Am Diet Assoc 99: 738-751   DOI   ScienceOn
26 Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595
27 Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. 2000. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 16: 1091-1097
28 Wang W, Goodman MT. 1999. Antioxidant property of dietary phenolic agents in a human LDL-oxidation ex vivo model: interaction of protein binding activity. Nutr Res 19: 191-202   DOI   ScienceOn
29 Huang MH, Harrison GG, Mohamed MM, Gornbein JA, Henning SM, Go VLW, Greendale GA. 2000. Assessing the accuracy of a food frequency questionnaire for estimating usual intake of phytoestrogens. Nutrition and Cancer 37: 145-154   DOI   ScienceOn
30 Korea National Statistical Office. 2003. Annual report on cause of death statistics
31 Adlercreutz H, Mazur W, Bartels P, Elomaa V, Watanabe S, Wahala K. 2000. Phytoestrogens and prostate disease. J Nutr 130: 658S-659S   DOI
32 DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM. 1998. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339: 785-791   DOI   ScienceOn
33 Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML. 1996. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271: 3154-3162   DOI
34 Rojas E, Lopez MC, Valverde M. 1999. Single cell gel electrophoresis assay: methodology and applications. J Chromatography B 722: 225-254   DOI   ScienceOn
35 Messina MJ. 2003. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 61: 117-131   DOI
36 Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. 1998. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 28: 360-363   DOI   ScienceOn
37 Claffey KP, Robinson GS. 1996. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15: 165-176   DOI   ScienceOn
38 Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. 1995. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549   DOI   ScienceOn
39 Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. 1999. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133   DOI   ScienceOn
40 Ferrara N, Davis-Smith T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25   DOI   ScienceOn
41 Torel J, Cillard J, Cillard P. 1986. Antioxidant activity of flavonoids and reactivity with peroxy radical. Phytochemistry 25: 383-385   DOI   ScienceOn
42 Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. 1993. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidants status in premature neonates. Clin Sci 84: 407-412   DOI
43 Hansen MB, Svenson M, Diamant M, Bendtzen K. 1993. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5: 72-80   DOI   ScienceOn
44 Miller NJ, Castellucio C, Tijburg L, Rice-Evans C. 1996. The antioxidant properties of theaflavins and their gallate esters-radical scavengers or metal chelators. FEBS Letters 392: 40-44   DOI   ScienceOn
45 Rice-Evans C, Miller NJ. 1994. Total antioxidant status in plasma and body fluids. Methods Enzymol 234: 279-293   DOI
46 Sachez-Rodriguez M, Mendoza-Nunez VM, Vargas-Guadarrama LA. 1998. Niveles de antioxidantes totales en una muestra de la poblaci?n gerontol?gica de la ciudad de Mexico. Bioquimia 23: 848-855
47 MacEwan DJ. 2002. TNF ligands and receptors - a matter of life and death. British J Pharmacology 135: 855-875   DOI   ScienceOn
48 Kirk EA, Sutherland P, Wang SA, Chait A, LeBoeuf RC. 1998. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor- deficient mice. J Nutr 128: 954-959   DOI
49 Urban D, Irwin W, Kirk M, Markiewicz MA, Myers R, Smith M, Weiss H, Grizzle WE, Barnes S. 2001. The effects of isolated soy protein in plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 165: 294-300   DOI   ScienceOn
50 Jenkins DJ, Kendall CW, D'Costa MA, Jackson CJ, Vidgen E, Singer W, Silverman JA, Koumbridis G, Honey J, Rao AV, Fleshner N, Klotz L. 2003. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol 169: 507-511   DOI   ScienceOn